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Bacterial loadThe aim of this study was to develop a quantitative 16S rRNA assay for determination of bacterial nucleic
acid load in cerebrospinal ﬂuid (CSF) shunt infection and to compare quantitative 16S rRNA polymerase
chain reaction (PCR) ﬁndings to those of conventional bacterial culture in patients treated for CSF
shunt infection.We developed a quantitative 16S rRNA PCR assay that detected bacterial load across a range of
2.5 × 109 down to 2.5 × 104 16S copies/mL CSF under experimental conditions for numerous Gram-positive
and Gram-negative organisms. However, when applied to archived CSF samples from 25 shunt infection
episodes, correlations between positive bacterial culture and 16S rRNA levels were seen in only half of
infections, and 16S rRNA levels dropped precipitously after an initial peak on the ﬁrst day of sample collection.
Bacterial load measured using 16S rRNA PCR does not provide sufﬁcient information beyond bacterial culture
to inform CSF shunt infection treatment.ed by STARS-kids; Clinical and
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Cerebrospinal ﬂuid (CSF) shunt placement has been the mainstay of
treatment for hydrocephalus for over 50 years (Kestle, 2003).While CSF
shunts allow patients to survive and avoid further brain injury, they can
cause new and often chronic surgical and medical problems. CSF shunt
infections are one such complication, causing 2200–2400 pediatric
hospital admissions each year in the U.S. (Simon et al., 2008).
CSF shunt infections are usually caused by bacterial pathogens
(Fan-Havard and Nahata, 1987; Nelson, 1984; Odio et al., 1984;
Sells et al., 1977) and are notoriously difﬁcult to treat. Because the
bacteria adhere to the shunt itself, treatment requires both surgical
management to remove and replace the shunt and medical therapy to
kill the bacteria. Medical treatment generally involves prolonged
intravenous (IV) antibiotic administration and occasionally intrathe-
cal antibiotics (Fan-Havard and Nahata, 1987; Kestle et al., 2006).
While IV antibiotics are a mainstay of clinical practice, duration of IV
antibiotic use varies widely—from 4 to 47 days in 1 study (Kestle et al.,
2006)—and may depend on both the surgical approach used (Nelson,
1984; Vinchon and Dhellemmes, 2006) and the pathogen involved
(Fan-Havard and Nahata, 1987; Younger et al., 1987). Available data
on optimal length of therapy are sparse. For children with ﬁrst CSF
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from 12 to 26% (Kestle et al., 2006; Kulkarni et al., 2001; Vinchon and
Dhellemmes, 2006). Rates of reinfection are higher still for children
with second infections (Tuan et al., 2011).
Risk factors for CSF shunt reinfection are not well-understood and
may be related to the management of the prior infection. Diagnosis and
management of CSF shunt infection currently rely on conventional
microbiologic cultures. The initial diagnosis is based on the recovery of a
pathogen from culture, and length of therapy is often based on the
number of days that cultures are positive. Conventional cultures can
require 24–48 hours for organism identiﬁcation, and the chances of
recovering a bacterium are signiﬁcantly reduced if the patient has
received prior antimicrobial therapy. CSF indices (e.g., glucose, protein,
cell count and differential, and Gram stain) are not always reliable in
identifying infection or tracking its progression (Lan et al., 2003);
however, theseparameters are often followedbyclinicians todetermine
duration of antimicrobial treatment and timing of shunt replacement.
CSF shunt replacement generally does not occur until negative CSF
cultures are obtained and the treatment course is completed.
Clinicians, patients, and their families clearly need better evidence to
guide the treatment of CSF shunt infection in order to avoid reinfection.
We recognized the increasing use of real-time polymerase chain
reaction (RT-PCR) technology targeting conserved regions of the 16S
rRNA gene was capable of detecting thousands of species of bacteria,
including themost frequent CSF shunt infection pathogens (Banks et al.,
2005; Blaschke and Voelkerding, 2006; Deutch et al., 2007). The
potential utility of 16S rRNA PCR for the detection of bacterial DNA has
been shown in otherwise sterile body ﬂuids including amniotic ﬂuid,
neonates with bacteremia, and neutropenic cancer patients with fever
as well as CSF (Banks et al., 2005; Won et al., 2012), but its utility in the
detection of infection has been limited. We wondered if 16S rRNA PCR
might be more beneﬁcial for guiding therapy. We developed a
quantitative 16S rRNA assay to quantify bacterial load and evaluate
changes in bacterial load in response to antibiotic therapy and surgical
management. The objectives of this study were to 1) develop a
quantitative 16S rRNA assay for the determination of bacterial nucleic
acid load in CSF shunt infection and 2) compare the ﬁndings of
quantitative 16S rRNA PCR to those of conventional bacterial culture in
patients treated for CSF shunt infection.2. Materials and methods
2.1. Primer selection
A panel of target organisms for assay development was generated
from those observed in CSF shunt infections at Primary Children's
Medical Center (PCMC) during a retrospective observational cohort
study conducted from 1997 to 2006 (Simon et al., 2012) (Table 1).
Sequences were aligned using Vector NTI Align X (Life Technologies,
Grand Island, NY, USA), and primers were designed to target
conserved sequences between organisms and to optimize primerTable 1
CSF shunt infection organisms targeted during 16S rRNA PCR primer design.
Gram positive Gram negative
Enterococcus spp. E. cloacae
Propionibacterium acnes E. coli
S. aureus Haemophilus spp.
Staphylococcus spp. (coagulase-negative) K. oxytoca
Streptococcus pneumoniae P. aeruginosa
Streptococcus spp. Serratia marcescens
Streptococcus viridans K. pneumoniaea
Corynebacterium spp.a
Micrococcus spp.a
a Organism was not an original target during primer design, but primer is able to
detect its 16S rRNA sequence based on alignment.characteristics. We selected a 17 base pair (bp) forward primer and a
21 bp reverse primer to amplify a 107 bp amplicon spanning bases
1149–1256 of the Escherichia coli 16S rRNA gene. The numbers of
copies of 16S rRNA for each bacterial species were determined from
the literature (Lee and Bussema, 2009). After we detected only low
amounts of 16S rRNA using this primer set, we tested samples using a
second set of previously published primers targeting the V6 region of
the 16S rRNA gene (Chakravorty et al., 2007) that also targets all
organisms shown in Table 1.
2.2. DNA extraction
We tested several conditions to extract bacterial DNA. Seven
organisms were used to test DNA extraction from CSF: Staphylococcus
aureus, Staphylococcus saprophyticus, Enterococcus faecalis, E. coli,
Klebsiella oxytoca, Enterobacter cloacae, and Pseudomonas aeruginosa
(ATCC, Manassas, VA, USA, and clinical isolates from Seattle Children's
Microbiology Lab). Cultures were grown overnight at 37° in LB broth
and were pelleted and resuspended in uninfected donated CSF, which
were then serially diluted using uninfected donated CSF to test
extraction efﬁciency across a wide range, and particularly, for lower
bacterial concentrations.
We initially tested approaches including Gentra Puregene (Qiagen,
Valencia, CA, USA) and the column-based QIAmp (Qiagen) DNA mini
kit, both using the body ﬂuids protocol, with the addition of either
lysozyme, cell lysis solution, proteinase K digestion, RNase digestion,
and/or heat disruption protocols in various combinations. We also
tested use of linear acrylamide, glycogen, and diluted glycogen to
improve recovery when low concentrations of bacteria were
expected, but bacterial contamination prevented the use of these
approaches. Direct CSF lysis was also attempted tomaximize recovery,
but this proved ineffective.
After initial approaches demonstrated low yields with Gram-
positive organisms, we switched to a more rigorous bead-beating cell
disruption protocol using 0.1-mm zircona/silica beads. These smaller
gauge beads were substituted into a standard MO BIO PowerSoil DNA
isolation kit (MO BIO Laboratories, Inc., Carlsbad, CA, USA) protocol
showing dramatic improvement in extraction efﬁciency. The ﬁnal
approach to DNA extraction in CSF employed direct lysis of 100-μL CSF
using MO BIO BiOstic bacteremia DNA isolation kit, a bead-beating
protocol optimized for the puriﬁcation of DNA (host and microbial)
from body ﬂuids. Volume for ﬁnal elution of genomic DNA was 50 μL.
2.3. Assay reﬁnement
Primers were synthesized by Integrated DNA Technologies (Iowa
City, IA, USA). RT-PCR was performed with an Agilent Mx3005P QPCR
System instrument using SYBR Green (Applied Biosystems; Life
Technologies, Grand Island, NY, USA) for detection of PCR products.
Each quantitative (qRT-PCR) reaction was performed in triplicate
and included 0.4 μL each of 10 μmol/L forward and reverse primers,
5.0 μL 2× SYBRGreen PCR master mix (Applied Biosystems), 3.2 μL of
ddH2O, as well as 1.0 μL of genomic DNA. Quantitative PCR cycling
conditions were as follows: 95 °C for 10 minutes, and 40 cycles of
95 °C for 15 seconds, 60 °C for 1 minute. After each assay, a
dissociation curve was run to conﬁrm speciﬁcity of all PCR amplicons.
Resulting crossing threshold values were converted to copy numbers
and expressed as the average of triplicate samples ± 1 SD. If an
individual well ampliﬁed poorly during qRT-PCR, the replicate was
removed from triplicate measurements.
2.4. Assay testing
Assay efﬁciency was determined for both Gram-positive and
Gram-negative CSF shunt infection organisms in dilution series of
genomic DNA suspended in 10 mmol/L Tris-HCl. Nine organisms were
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S. aureus, S. saprophyticus, E. faecalis, S. pneumoniae, E. coli, K. oxytoca,
E. cloacae, P. aeruginosa, and Haemophilus inﬂuenzae (ATCC); Staph-
ylococcus epidermidiswas provided by the Blaschke lab. Bacteria were
harvested, and DNA was extracted using the Gentra Puregene
(Qiagen) bacteria protocol including a lysozyme digest. Dilution
series were created and qRT-PCR was performed (Fig. 1).
To generate quantiﬁcation curves, puriﬁed DNA from S. aureus and
E. coli bacteria in CSF was quantiﬁed using a PicoGreen DNA
quantitation kit (Molecular Probes®; Life Technologies). This DNA
was subsequently diluted serially by copy number (calculated by
molecular weight) and ampliﬁed using the 16S rRNA qRT-PCR
assay (Fig. 2).
2.5. Samples from children with CSF shunt infection
Children b18 years old undergoing treatment for conventional
culture-conﬁrmed CSF shunt infection at either SCH or PCMC wereFig. 1. qRT-PCR for 16S rRNA showing dilution series of genomic DNA in water from 9 CSF
K. oxytoca, E. cloacae, P. aeruginosa, and H. inﬂuenzae). Nine species of bacteria were cultured,
and tested using the 1149f and 1256r primers.eligible for enrollment in this study. A CSF shunt infectionwas deﬁned
as identiﬁcation of organisms on microbiological culture of CSF ﬂuid
obtained from a partial or complete CSF shunt system. CSF shunt
system(s) included ventriculoperitoneal, ventriculoatrial, ventriculo-
pleural, arachnoid cyst shunts, subdural shunts, and lumboperitoneal
shunts, while temporary devices only such as external ventricular
drain(s), Ommaya reservoir(s), ventricular access devices (reser-
voirs), and subgaleal shunts were not included. For all study subjects,
except those from PCMC prior to March 18, 2010, parental permission
(and assent when appropriate) was obtained for additional CSF to be
collected on each occasion that regular CSF samples were obtained
during treatment for CSF shunt infection. Prior to March 18, 2010, at
PCMC, we used CSF remaining after routine processing and testing in
the PCMC Microbiology Laboratory. The ﬁrst CSF sample for diagnosis
of infection was usually obtained from needle aspiration of the shunt
reservoir under sterile conditions outside the operating room in a
bedside “shunt tap”. The initial CSF sample analyzed in this study
either was leftover from this ﬁrst diagnostic sample or was obtainedshunt infection organisms (S. aureus, S. saprophyticus, E. faecalis, S. pneumoniae, E. coli,
and genomic DNA was extracted. Dilution series for each bacterial species were created
Fig. 2. qRT-PCR for 16S rRNA showing standard copy number curves for S. aureus and E. coli bacteria in CSF. Panel A demonstrates a standard curve of S. aureus bacteria in CSF.
Panel B demonstrates a standard curve of E. coli bacteria in CSF. Panel C demonstrates melt curves for both S. aureus (Tm 81.3 °C) and E. coli (Tm 82.8 °C) PCR amplicons.
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removed during the ﬁrst surgery to treat infection. Subsequent CSF
samples, including those at the end of the infection, were generally
obtained under sterile bedside conditions through a sampling port
within sterile extension tubing attached to the external ventricular
drain. The study received Institutional Review Board approval from
the Seattle Children's Research Institute and the University of Utah, as
well as approval from the PCMC Privacy Board.
After CSF was obtained for the study, CSF was stored at 4 °C. For a
minority of samples, CSF was stored in solution provided in the MO
BIO BiOstic bacteremia DNA isolation kit; storage in this solution did
not affect recovery of bacterial DNA. CSF was then aliquoted for the
study and stored at−70 °C; PCMC samples were shipped overnight to
Seattle on dry ice.
2.6. Analysis
DNA from 100 μL of CSF was extracted for each available sample
over the course of infection treatment. BVY performed the 16S rRNA
qRT-PCR assay in triplicate. CSF samples tested included a selection
among children for whom consistent CSF sample collection wasFig. 3. A representative example of 16S rRNA PCR over the course of infection treatment for a
V6 (B). For A, concurrent negative controls of CSF alone produced a relative quantity of 232,
alone produced a relative quantity of 238,500–272,000 copies of 16S per milliliter CSF.obtained over the course of infection. Negative controls included
phosphate-buffered saline and uninfected donor CSF. We tested the
original primers in 25 infection episodes total; for 13 of these
infections, we also performed analysis using the V6 primers. We
compared the results of each 16S rRNA PCR series to each other, as
well as to conventional culture results.
3. Results
Testing serial dilutions of genomic DNA from Gram-positive and
Gram-negative CSF shunt infection organisms in water demonstrated
the ability of our qRT-PCR to detect bacterial DNA across a wide range
of species (Fig. 1, data not shown for S. epidermidis). Some slight
variation existed when comparing ampliﬁcations between species,
but generally, the assay was highly efﬁcient and linear regardless of
bacterial template (average efﬁciency 97.4%, average RSq 0.996).
Ampliconmelting temperatures were similar for all organisms (81 °C)
except for S. pneumoniae and P. aeruginosa, which had slightly lower
(80 °C) and slightly higher (83 °C) melt temperatures, respectively.
The assay's ability to detect quantiﬁed amounts of 16S rRNA DNA
was demonstrated with linearity across a range of 2.5 × 109 copies/mLsingle infection episode (P) using the original primer set (A) and the primers targeting
500–265,000 copies of 16S per milliliter CSF. For B, concurrent negative controls of CSF
Table 2
Determination of bacterial load with quantitative 16S rRNA DNA PCR using original and V6 primers, compared conventional bacterial culture ﬁndings only when cultures
demonstrated organisms.
Patient Day Bacterial culture Original primer 16S copy number per ml CSF V6 primer 16S copy number per mL
CSF (if tested)
A. Coagulase-negative Staphylococcus only (n = 11). We had insufﬁcient CSF to obtain PCR data for J and N on day 1, as well as B on day 1 and K on day 2.
A 1 S. epidermidis 477,000–835,000 n/a
B 5 S. epidermidis 253,000–328,500 227,500–235,500
C 1 Staphylococcus lugdunensis 194,000–280,500 n/a
2 S. lugdunensis 188,500–281,000 n/a
E 1 Coagulase-negative Staphylococcus 211,850–247,150a and 384,200–453,950 and 344,050–358,200 n/a
3 Coagulase-negative Staphylococcus 201,050–242,750a n/a
F 1 Coagulase-negative Staphylococcus 3,627,000–3,600,050 n/a
G 1 S. epidermidis 52,500–70,000 n/a
I 1 S. epidermidis 26,850–90,500 n/a
2 S. epidermidis 211,500–232,000 n/a
3 S. epidermidis 173,000–244,500 n/a
4 S. epidermidis 171,000–187,000 n/a
K 1 S. epidermidis 435,500–483,000 n/a
M (#2) 1 S. epidermidis 206,050–220,300 193,000–216,000
2 S. epidermidis 129,100–164,050 150,500–171,000
3 S. epidermidis 129,050–145,750 142,000–150,500
4 S. epidermidis 106,500–147,250 and 133,000–197,850 103,500–117,500 and 156,500–177,500
B. Other single infecting organisms (n=8).We had insufﬁcient CSF to obtain PCR data for H (#2) on day 1with S. aureus, as well as T on day 3with Serratia marcescens, R on day 2
with E. faecalis and L on day 7 with Propionibacterium acnes.
D 1 S. aureus 153,500–165,000a n/a
L 1 P. acnes 2,355,000–2,765,000 n/a
2 P. acnes 168,500–225,000 n/a
M (#1) 1 Group A beta-hemolytic Streptococcus 406,400–565,000 445,500–610,000
O 1 P. acnes 77,000–100,500 66,500–73,250
P 1 E. coli 3,225,000–3,785,000 3,205,000–3,325,000
R 1 E. faecalis 256,500–314,500 306,500–324,000
T (#2) 1 S. marcescens 950,000–1,150,000 1,125,500–1,331,500
2 S. marcescens 195,000–225,500 202,800–240,300
C. Infections with a several organisms (n= 6). We had insufﬁcient CSF to obtain PCR data for S (#2) on day 1 with S. epidermidis, Staphylococcus warneri, and Diphtheroid bacilli,
as well as for Q on day 1 with S. pneumoniae, S (#1) on day 17 and 18 withMicrococcus spp., and T (#1) on days 4 and 6 with S. aureus and day 11 with Staphylococcus hominis.
H (#1) 1 S. epidermidis and S. aureus 7,050,000–7,800,000 n/a
3 S. aureus 96,500–145,000a and 85,500–100,500a and 78,500–114,500a n/a
4 S. aureus 21,550–164,000a and 4,670–27,550 n/a
5 S. aureus 108,000–163,500a and 71,000–123,000a n/a
6 S. aureus 110,000–131,000a and 42,850–60,500 n/a
Q 3 No growth 3,140,000–3,775,000 3,440,000–4,080,000
5 Staphylococcus capitis 940,000–1,165,000 1,020,000–1,525,000
S (#1) 1 Corynebacterium spp. 406,400–565,000 148,000–181,500
10 Corynebacterium spp. 138,450–151,050 204,000–241,000
11 Corynebacterium spp. 289,350–347,150 211,500–267,000
12 Corynebacterium spp. 201,750–366,900 177,500–187,500
T (#1) 1 S. aureus 133,500–202,500 96,000–116,500
2 S. aureus 234,500–256,500a 199,000–205,500
3 S. aureus 175,000–219,500a 103,500–111,500
5 S. aureus 226,500–293,500a 224,000–239,000a
16 Coagulase-negative Staphylococcus 291,000–336,000 258,000–293,500
U 1 K. pneumoniae and Streptococcus mitis/oralis 318,350–383,650 349,650–471,950
3 K. pneumoniae 137,850–159,900 151,400–177,300
5 K. pneumoniae 177,050–192,950 181,850–265,100
16 S. epidermidis and S. aureus 92,200–124,450 91,100–153,500
Subsequent days of infection treatment with negative CSF cultures are not provided here. Bolded primer counts are signiﬁcantly different from negative CSF controls and
later (culture-negative) samples drawn during the infection episode; these examples resemble the representative infection episodes shown in Figs. 3A and 3B.
a Above CSF negative controls, but not different from other samples drawn during the infection episode.
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mL CSF using standard copy number curves of S. aureus (efﬁciency
107.1%, RSq 1.000) and E. coli (efﬁciency 105.4%, RSq 1.000) bacterial
templates (Fig. 2).
Data from 16S rRNA ampliﬁcation in a representative infection
episode are shown in Fig. 3. After an initial peak on the ﬁrst day of
sample collection, levels of quantitative 16S rRNA dropped precipi-
tously and thereafter remained comparable to negative controls with
both primer sets. The quantitative 16S rRNA PCR assays using the
original and V6 primers were well correlated.
A summary of ﬁndings for all 25 infection episodes is shown in
Table 2. Relative quantities of 16S above baseline, which might be
expected in the presence of CSF that grew organisms in culture, wereonly observed intermittently. As demonstrated for the representative
infection shown in Fig. 3, levels of quantitative 16S rRNA dropped
precipitously after the ﬁrst day of sample collection across all samples
(data not shown). Correlations between positive bacterial culture and
quantitative 16S rRNA levels did not differ by infecting organism and
were seen in only 4 of 9 (44%) infections with coagulase-negative
Staphylococcus, 4 of 7 (57%) infections with other single organisms,
and 4 of 5 (80%) infections with mixed organisms (Table 2). Results
using the original and V6 primers again correlated well. For 3 of 4
infections in children who went on to develop reinfections (H, M, T),
we also examined levels of 16S rRNA PCR at the end of the initial
infection episode. None of these levels were above that of the negative
controls at the end of the ﬁrst infection treatment (data not shown).
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We hypothesized that ampliﬁcation of bacterial DNA using 16S
rRNA PCR could be used as a marker of CSF bacterial load and might
be useful to inform antibiotic management and timing of shunt
replacement to avoid reinfection. We developed a quantitative 16S
rRNA PCR assay that demonstrated an ability to detect genomic
DNA from both Gram-positive and Gram-negative CSF shunt infec-
tion organisms across a range of 2.5 × 109 copies/mL CSF down to a
detection limit of approximately 2.5 × 104 16S copies/mL CSF under
experimental conditions. However, when this assay was applied to
clinical samples, there was inconsistent detection of 16S rRNA over
background levels when compared to bacterial culture. Levels of 16S
rRNA at the end of infection did not correlate with reinfection. This
quantitative 16S rRNA PCR assay did not augment treatment
information provided by conventional CSF cultures among children
undergoing treatment for CSF shunt infection.
Previous work has examined the use of 16S PCR for the rapid
detection of CSF shunt infection (Banks et al., 2005) or in external
ventricular drain infections (Deutch et al., 2007). The use of broad-
range 16S rRNA PCR for the detection of pathogens has the potential
advantage of unbiased ampliﬁcation of any bacterial species present
(Nadkarni et al., 2002) and thus could theoretically be used for
infections caused by a range of organisms. While initial data for broad
range PCR were promising, (Banks et al., 2005; Blaschke and
Voelkerding, 2006; Deutch et al., 2007; Won et al., 2012), more
recent studies have demonstrated signiﬁcant limitations due to the
ubiquitous nature of bacterial DNA and the high rate of false-positive
detection (Corless et al., 2000; Millar et al., 2002). Due to high
background levels of bacterial DNA, the extended PCR cycling
required for optimal detection of organisms present in low concen-
trations cannot be performed (Sontakke et al., 2009).
Because of the well-documented sensitivity issues with broad-
range bacterial ampliﬁcation, we were seeking to use 16S PCR not to
diagnose infection but to quantify bacterial load in culture-documen-
ted infection as a method to guide antibiotic management. While our
experimental quantiﬁcation curves showed good correlation between
bacterial load and 16S copy number, this did not translate to practical
data with utility for guiding management of CSF infection. Some
authors have advised use of both 16S PCR and conventional culture
in clinical scenarios (Deutch et al., 2007; Sarookhani et al., 2010).
In our hands, the PCR did not add sufﬁcient information to justify its
routine clinical use. It is likely that the ability of our assay to detect
bacterial load was complicated by low levels of bacterial DNA present
in samples, particularly after the removal of CSF shunt and initiation
of antibiotic treatment.
Measurement of viral load using quantitative real-time PCR is an
established method to guide therapy in viral infections such as those
caused by cytomegalovirus and human immunodeﬁciency virus
(Berger and Preiser, 2002). The use of quantitative bacterial PCR in
clinical care is less well-established. Literature supports its potential
beneﬁt in the diagnosis and evaluation of disease severity in
pneumococcal pneumonia and pneumococcal sepsis as well as in
meningococcal disease (Darton et al., 2009; Peters et al., 2004; Rello
et al., 2009). Studies that use bacterial load to guide therapeutic
management are rarer still.
Conventional culture techniques examine free-ﬂoating clonal
populations of a single species during logarithmic growth phase
(Rhoads et al., 2012). In contrast, bioﬁlms are surface-associated
groups, often composed of multiple genera, of organisms held
together by an extracellular matrix, and both the growth conditions
and population within the bioﬁlm can be spatially and temporally
variable (Rickard et al., 2003). These complex communities attach to
surfaces in a largely dormant mode (Bayston et al., 2012) that
promotes resistance to antibiotics. Bioﬁlms have been implicated in
several chronic infections (Costerton et al., 1999). Some work hassuggested the presence of bioﬁlms on CSF shunts (Fux et al., 2006;
Guevara et al., 1987). One possible explanation of our ﬁndings is that
bioﬁlms are present in CSF shunt infections, and bacterial DNA is only
periodically detected by either 16S PCR or conventional culture in CSF
due to the highly dormant state of bacteria in these communities.
Nonetheless, reinfection occurs at high rates. This apparent paradox
indicates a need to consider different models for understanding the
microbial environment in CSF shunt infection.
This pilot study took the ﬁrst step to examine the utility of
molecular quantiﬁcation of CSF pathogens for patients undergoing
treatment for CSF shunt infection. Based on our data, we conclude that
molecular quantiﬁcation of bacterial load using broad-range 16S rRNA
PCR does not appear useful as a novel adjunct to optimize treatment of
CSF shunt infection. It is possible that other approaches, such as
examination of bioﬁlm, species-speciﬁc ampliﬁcation, and/or markers
of inﬂammation may be more suitable, and these approaches deserve
further study. For the moment, clinicians continue to require an
optimal treatment strategy for CSF shunt infections that accurately
determines when bacteria have been eradicated and reinfection after
shunt replacement is unlikely.
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